Journal profile · Medicine-Oncology
Cancer Treatment and Research Communications
ISSN 2468-2942 · Elsevier · United Kingdom
Cancer Treatment and Research Communications: CAS Zone 4 · Medicine (2026 Xinrui edition); impact factor 3.5 (journal website); fully open access; APC about USD 2,940; median 109 days to acceptance (122 articles, last 24 months); 210 articles in 2025; indexed in ESCI and Scopus.
Scope
Aims, scope and focus
Cancer Treatment and Research Communications is published by Elsevier and is classed under Medicine in the CAS Journal Ranking. By OpenAlex counts of its recent articles, its largest topics are Lung Cancer Treatments and Mutations, Lung Cancer Diagnosis and Treatment and Cancer Immunotherapy and Biomarkers, together about 32% of its articles. Its main subfields are Oncology and Pulmonary and Respiratory Medicine. (generated from OpenAlex topic counts and CAS ranking data)
Cancer Treatment and Research Communications is an international peer-reviewed journal dedicated to providing comprehensive basic, translational, and clinical oncology research. The journal is devoted to articles on detection, diagnosis, prevention, and treatment of cancer and provides a global forum for the nurturing and development of future generations of oncology scientists. Specific areas of interest include basic, translational, and clinical research and mechanistic approaches in all tumor types; cancer biology; molecular carcinogenesis; cancer genetics and genomics; cancer stem cells; molecular and cellular oncology; systems biology; immuno-oncology; chemoprevention strategies; gene and antisense therapy; the pathology of cancer, prognostic and predictive markers; drug sensitivity and resistance and novel treatment strategies to impact patient care. The journal also accepts clinical studies in oncology, with an emphasis on prospective early phase clinical trials.Our mission is to be the premier source of relevant information through promoting excellence in research and facilitating the timely translation of that science to health care and clinical practice. Peer reviewed types of articles include Original Reports, Reviews and Editorials. The journal will not consider Case Reports or articles related to Cancer Policy.
From the journal's Aims & Scope
Research area (LetPub): Medicine-Oncology
Editor-in-chief Vincent ChungPublisher website
Editorial board by country: 16 in mainland China (about 4%); most named United States 143, Italy 39, India 31, Mainland China 16, Türkiye 13 (364 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Lung Cancer Treatments and MutationsMedicine14%
- Lung Cancer Diagnosis and TreatmentMedicine9.1%
- Cancer Immunotherapy and BiomarkersMedicine9%
- Lung Cancer Research StudiesMedicine8.2%
- Breast Cancer Treatment StudiesBiochemistry, Genetics and Molecular Biology6.7%
- Cancer Genomics and DiagnosticsBiochemistry, Genetics and Molecular Biology4%
- HER2/EGFR in Cancer ResearchMedicine3.8%
- Global Cancer Incidence and ScreeningMedicine3.5%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Not covered
Not covered by this edition.
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Not covered
Not covered by this edition.
Database indexing
ESCIScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor (publisher)
- 3.5Publisher website ·
- CiteScore 2026-06
- 5LetPub ·
- CiteScore (publisher)
- 5Publisher website ·
- SJR 2026-06
- 1LetPub ·
- SNIP 2026-06
- 1.01LetPub ·
- h-index
- 38OpenAlex ·
- i10-index
- 300OpenAlex ·
- 2-year mean citedness
- 1.27OpenAlex ·
- Self-citation rate
- 2.9%LetPub ·
- Share of gold OA articles
- 100%LetPub ·
Volume
- Articles per year
- 196LetPub ·
Articles by year OpenAlex count · 1,374 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 357 | 357 | 56 |
| 2025 | 210 | 210 | 261 |
| 2024 | 81 | 81 | 508 |
| 2023 | 102 | 102 | 762 |
| 2022 | 167 | 167 | 1,863 |
| 2021 | 197 | 197 | 3,008 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
109 daysMedian, submission to acceptance · P25–P75 54 days – 199 days
- Acceptance to online
- median 7 days (122 articles)
- Submission to online
- median 123 days
- Sample
- 122 articles with submission and acceptance dates (569 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 17 weeksLetPub ·
- Submission to first decision
- 8 daysPublisher website ·
- First decision after review
- 56 daysPublisher website ·
- Submission to acceptance
- 130 daysPublisher website ·
- Acceptance to publication
- 2 daysPublisher website ·
- Submission to publication (journal-reported)
- about 20 weeksDOAJ ·
- Peer review
- Single anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | USD 2,940 | Yes | CC BY, CC BY-NC, CC BY-NC-ND | |
| OpenAlex | USD 2,740 / EUR 2,560 / GBP 2,190 / JPY 339,840 | — | — | |
| Publisher website | USD 3,120 | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare3 items from the author guidelines
- Abstract
- ≤ 250 words
- Keywords
- 1–7
- Not considered
- Case Reports; articles related to Cancer Policy
Article types accepted9, with length limits
- commentaryibutions are not considered. Mechanics: Commentaries have a limit of 1,500 words and no more than 10 references. Authors are asked to limitmain text ≤ 1,500 words
- editorialsPeer reviewed types of articles include Original Reports, Reviews and Editorials.Length not stated
- lettercted and invited to respond. Mechanics: Letters have a limit of 1,000 words and no more than 10 references. Authors are asked to limitmain text ≤ 1,000 words
- opinionthout any published support. Mechanics: Opinion articles have a limit of 2,500 words and no more than 60 references. Authors are asked to limitmain text ≤ 2,500 words
- original reportsPeer reviewed types of articles include Original Reports, Reviews and Editorials.Length not stated
- original research articles and Methods, Results and Discussion). Original research articles have a limit of 4,500 words and no more than 50 references. Authors are asked to limitmain text ≤ 4,500 words
- perspectivenal Inbox: ctrc@elsevier.com Mechanics: Perspectives have a limit of 1,200 words and no more than 10 references. Authors are asked to limitmain text ≤ 1,200 words
- reviewtroduction, discussion, and conclusion. Reviews have a limit of 4,500 words and no more than 80 references. Authors are asked to limitmain text ≤ 4,500 words
- reviewsPeer reviewed types of articles include Original Reports, Reviews and Editorials.Length not stated
Policy excerpts from the journal's websiteAI use, Authorship, Conflicts of interest, Publication ethics, License & copyright, Open access, Peer review, Preprints
- AI use Declaration of generative AI use
Authors must declare the use of generative AI tools in the manuscript preparation process upon submission of the paper.Generative AI and AI-assisted technologies (“AI tools”) have been rapidly adopted in research and scholarly publishing, offering significant benefits while requiring clear standards for responsible and transparent use.Authors preparing a manuscript for this journal may use AI tool…
Source ↗Publisher website ·- Authorship Group authorship
Group authorship refers to the attribution of an article to a defined and named group of authors whose members have contributed to the work. Examples include research consortia, clinical trial groups, collaborative networks, task forces or working groups, expert panels or consensus groups, and participatory research groups. Group authorship must be declared on the title page at submission. When av…
Source ↗Publisher website ·- Conflicts of interest Declaration of competing interests
All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence or bias their work. Examples of potential competing interests include:EmploymentConsultanciesStock ownershipHonorariaPaid expert testimonyPatent applications or registrationsGrants or any other fundingAffiliation with the journal as an Editor or Advisory Board …
Source ↗Publisher website ·- Publication ethics
Follows Elsevier's Publishing Ethics Policy Model summary
Authors must follow ethical guidelines stated in Elsevier's Publishing Ethics Policy.
Source ↗Publisher website ·- License & copyright License options
Authors will be offered open access user license options which will determine how you, and third parties, can reuse your open access article. We advise that you review these options and any funding body license requirements before selecting a license option.
Source ↗Publisher website ·- Open access Open access
We refer you to our open access information page to learn about open access options for this journal.
Source ↗Publisher website ·- Peer review Peer review
Single anonymized review process Model summary
This journal follows a single anonymized review process. Your submission will initially be assessed by our editors. If your submission is deemed suitable, it will typically be sent to be reviewed by a minimum of two reviewers for an independent expert assessment of the scientific quality. The decision as to whether your article is accepted or rejected for publication will be made by our editors.Re…
Source ↗Publisher website ·- Preprints Preprints
Preprint sharing allowed, does not count as prior publication Model summary
Preprint sharingAuthors may share preprints in line with Elsevier's article sharing policy. Sharing preprints, such as on a preprint server, will not count as prior publication.We advise you to read our policy on multiple, redundant or concurrent publication. In support of Open Science, this journal offers its authors a free preprint posting service on SSRN, Elsevier’s preprint and early research …
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Elsevier
- Country or region
- United Kingdom
- Language
- English
- ISSN
- 2468-2942
- Official links
- Journal homepage ↗DOAJ
- Submission system ↗Publisher website
- Author guidelines ↗DOAJ
- Aims & Scope ↗DOAJ
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗DOAJ
- Editorial board ↗DOAJ
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about Cancer Treatment and Research Communications
What CAS zone is Cancer Treatment and Research Communications in?
In the 2026 Xinrui edition it is in Zone 4 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Cancer Treatment and Research Communications?
The journal's website gives an impact factor of 3.5; this is the journal's own figure, as LetPub lists none for it; CiteScore 5, h-index 38.
How long does peer review take at Cancer Treatment and Research Communications?
Based on the dates recorded on 122 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 109 days (interquartile range 54–199 days); authors report an average review time of about 17 weeks. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of Cancer Treatment and Research Communications?
According to the journal's author guidelines: Abstract: ≤ 250 words; Keywords: 1–7. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of Cancer Treatment and Research Communications based?
Of the 364 board members whose country the journal's board page names, 16 (about 4%) are in mainland China; the countries named most often are United States (143), Italy (39) and India (31). Counted from the institutions listed on the board page; for reference only.
Which databases index Cancer Treatment and Research Communications?
According to LetPub and DOAJ records, Cancer Treatment and Research Communications is indexed in ESCI, Scopus and DOAJ.
Is Cancer Treatment and Research Communications open access, and what is the APC?
Cancer Treatment and Research Communications is a fully open-access journal. APC about USD 2,940.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex, DOAJ; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .